Drugs & Aging

, Volume 24, Issue 6, pp 489–499

Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients

  • John R. Bartholomew
  • Carolynn E. Pietrangeli
  • Marcie J. Hursting
Original Research Article
  • 31 Downloads

Abstract

Background

Argatroban, a direct thrombin inhibitor that has reduced clearance in elderly versus younger volunteers, is used for thromboprophylaxis or treatment in heparin-induced thrombocytopenia (HIT).

Objective

To evaluate the effect of aging on argatroban therapy, including dosage, anticoagulant responses, clinical outcomes and factors influencing those responses, in elderly patients with HIT or a history of HIT.

Methods

This was a retrospective multicentre database analysis of 118 inpatients treated with argatroban at six medical centres between August 2001 and January 2005. Sixty-two adults aged ≥;65 years were administered argatroban for clinically diagnosed HIT (n = 54) or a history of HIT (n = 8). Argatroban infusion was adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5–3 times baseline. All study measures and analyses were prospectively defined. Argatroban dosage patterns, aPTTs and platelet count responses, and 37-day outcomes (death, amputation, new thrombosis, major bleeding) were summarised for patients stratified by age (65–74 years [n = 31]; 75–84 years [n = 26]; ≥85 years [n = 5]) to identify possible age-related trends. Regression analyses explored relationships between dose and patient age, liver function and renal function. Cox proportional hazards models evaluated the effect of age, dose, gender, aPTT and platelet count on the risk of new thrombosis.

Results

In each age group, the median argatroban dosage was initially 1.0 µg/kg/min and was generally maintained at or near that dose during therapy (median, 5–7 days). Therapeutic aPTTs occurred within 11.5 hours; the median aPTT during therapy was 54.7 seconds, without obvious trend by age. By regression analysis, the initial and mean argatroban dosages decreased 0.08–0.09 µg/kg/min with each 0.2 mg/dL increase in serum creatinine, but no association was detected between dose and patient age, serum total bilirubin, calculated creatinine clearance or blood urea nitrogen. Platelet counts recovered within 6–7 days of initiating therapy, without apparent trend by age. No patient experienced amputation or major bleeding, and no patient in the oldest group died or had new thrombosis. Overall, 13 (21%) patients died (9 in the 65–74 years group; 1 receiving argatroban) and 5 (8%) had new thrombosis (4 in the 65–74 years group; 2 receiving argatroban), comparing favourably with previously reported rates, irrespective of patient age. By univariate (but not multivariate) analysis, the risk of new thrombosis decreased with increasing argatroban dose (hazard ratio 0.020; 95% CI 0.001, 0.757; p = 0.035). No effect of age or the other covariates considered on thrombotic risk was detected.

Conclusion

Argatroban at a median initial dosage of 1.0 µg/kg/min, adjusted to achieve median aPTTs of 54.7 seconds during therapy, generally provided safe, adequate anticoagulation across a wide age range in elderly patients with HIT or a history of HIT. In these elderly patients, age was not a significant determinant of argatroban dosage or thrombotic risk. Prospective evaluation of this initial dose of argatroban in the elderly is warranted.

References

  1. 1.
    DeLoughery TG. Critical care clotting catastrophes. Crit Care Clin 2005 Jul; 21(3): 531–62PubMedCrossRefGoogle Scholar
  2. 2.
    Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118(2): 165–76PubMedCrossRefGoogle Scholar
  3. 3.
    Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005 May 24; 111(20): 2671–83PubMedCrossRefGoogle Scholar
  4. 4.
    Tardy-Poncet B, Tardy B. Heparin-induced thrombocytopenia: minimising the risks in the elderly patient. Drugs Aging 2000 May; 16(5): 351–64PubMedCrossRefGoogle Scholar
  5. 5.
    Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838–43PubMedCrossRefGoogle Scholar
  6. 6.
    Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003 Aug 11–25; 163(15): 1849–56PubMedCrossRefGoogle Scholar
  7. 7.
    Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997 Sep; 56(1): 12–6PubMedCrossRefGoogle Scholar
  8. 8.
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996 Nov; 101(5): 502–7PubMedCrossRefGoogle Scholar
  9. 9.
    Bartholomew JR. The incidence and clinical features of heparin-induced thrombocytopenia. Semin Hematol 2005 Jul; 42 (3 Suppl. 3): S3–8PubMedCrossRefGoogle Scholar
  10. 10.
    Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004 Feb 23; 164(4): 361–9PubMedCrossRefGoogle Scholar
  11. 11.
    Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311S–37SPubMedCrossRefGoogle Scholar
  12. 12.
    Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006 May; 133(3): 259–69PubMedCrossRefGoogle Scholar
  13. 13.
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001 Apr 26; 344(17): 1286–92PubMedCrossRefGoogle Scholar
  14. 14.
    Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502–6PubMedGoogle Scholar
  15. 15.
    Escolar G, Bozzo J, Maragall S. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today (Barc) 2006 Apr; 42(4): 223–36CrossRefGoogle Scholar
  16. 16.
    Matthai Jr WH, Hursting MJ, Lewis BE, et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005; 116(2): 121–6PubMedCrossRefGoogle Scholar
  17. 17.
    Levine R, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129(5): 1167–75PubMedCrossRefGoogle Scholar
  18. 18.
    Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000 Mar; 20(3): 318–29PubMedCrossRefGoogle Scholar
  19. 19.
    Baghdasarian S, Singh I, Militello M, et al. Argatroban dosage in critically ill patients with HIT [abstract]. Blood 2004; 104(11): 493aGoogle Scholar
  20. 20.
    Koster A, Buz S, Hetzer R, et al. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006 Sep; 132(3): 699–700PubMedCrossRefGoogle Scholar
  21. 21.
    Zahn R, Hamm CW, Schneider S, et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent: results from the prospective multicenter German Cypher Stent Registry. Am Heart J 2006; 152(6): 1146–52PubMedCrossRefGoogle Scholar
  22. 22.
    Bhattacharya S, Saha SP, Basu A, et al. A 5-years prospective study of incidence, morbidity and mortality profile of stroke in a rural community of eastern India. J Indian Med Assoc 2005; 103(12): 655–9PubMedGoogle Scholar
  23. 23.
    Kaushik S, Tan AG, Mitchell P, et al. Prevalence and associations of enhanced retinal arteriolar light reflex: a new look at an old sign. Ophthalmology 2007; 114(1): 113–20PubMedCrossRefGoogle Scholar
  24. 24.
    De Lusignan S, Hague N, van Vlymen J, et al. A study of cardiovascular risk in overweight and obese people in England. Eur J Gen Pract 2006; 12(1): 19–29PubMedCrossRefGoogle Scholar
  25. 25.
    Maio V, Yuen EJ, Novielli K, et al. Potentially inappropriate medication prescribing for elderly outpatients in Emilia Romagna, Italy: a population-based cohort study. Drugs Aging 2006; 23(11): 915–24PubMedCrossRefGoogle Scholar
  26. 26.
    Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations. Drugs Aging 2006; 23(12): 969–76PubMedCrossRefGoogle Scholar
  27. 27.
    Egger SS, Bachmann A, Hubmann N, et al. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging 2006; 23(10): 823–37PubMedCrossRefGoogle Scholar
  28. 28.
    Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23(2): 167–78PubMedCrossRefGoogle Scholar
  29. 29.
    Saab YB, Hachem A, Sinno S, et al. Inappropriate medication use in elderly Lebanese outpatients: prevalence and risk factors. Drugs Aging 2006; 23(9): 743–52PubMedCrossRefGoogle Scholar
  30. 30.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRefGoogle Scholar
  31. 31.
    Cox D. Regression models and life tables. J Royal Stat Soc Series B 1972; 24: 187–220Google Scholar
  32. 32.
    Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–65PubMedCrossRefGoogle Scholar
  33. 33.
    Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756–70PubMedCrossRefGoogle Scholar
  34. 34.
    Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004; 38: 25–9PubMedCrossRefGoogle Scholar
  35. 35.
    Smythe M, Stephens JL, Koerber JM, et al. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 2005; 11: 371–4PubMedCrossRefGoogle Scholar
  36. 36.
    Kiser TH, Jung R, MacLaren R, et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25: 1736–45PubMedCrossRefGoogle Scholar
  37. 37.
    Kodityal S, Nguyen PH, Kodityal A, et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006; 21: 86–92PubMedCrossRefGoogle Scholar
  38. 38.
    Murray PT, Reddy BV, Grossman EJ, et al. A prospective study of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004; 66: 2446–53PubMedCrossRefGoogle Scholar
  39. 39.
    Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005; 39: 231–6PubMedCrossRefGoogle Scholar
  40. 40.
    Guzzi LM, Hursting MJ, McCollum DA. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006; 22: 169–76PubMedCrossRefGoogle Scholar
  41. 41.
    Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006 Jan; 81(1): 36–44PubMedCrossRefGoogle Scholar
  42. 42.
    Arepally GM, Ortel TL. Clinical practice: heparin-induced thrombocytopenia. N Engl J Med 2006 Aug 24; 355(8): 809–17PubMedCrossRefGoogle Scholar
  43. 43.
    Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101(1): 31–7PubMedCrossRefGoogle Scholar
  44. 44.
    Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 3rd ed. New York (NY): Marcel Dekker, 2004: 335–70Google Scholar
  45. 45.
    Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005 Jun; 19(3): 183–8PubMedCrossRefGoogle Scholar
  46. 46.
    Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005 Jul 2005; 11(3): 279–87CrossRefGoogle Scholar
  47. 47.
    Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 2004 Jun; 91(6): 1137–45PubMedGoogle Scholar
  48. 48.
    Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001 Mar; 85(3): 435–40PubMedGoogle Scholar
  49. 49.
    Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004 Jan 12; 164(1): 66–70PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • John R. Bartholomew
    • 1
  • Carolynn E. Pietrangeli
    • 2
  • Marcie J. Hursting
    • 3
  1. 1.The Cleveland ClinicClevelandUSA
  2. 2.CTI Clinical Trial and Consulting ServicesCincinnatiUSA
  3. 3.Clinical Science ConsultingAustinUSA
  4. 4.Department of Cardiovascular MedicineThe Cleveland ClinicClevelandUSA

Personalised recommendations